Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | SYK | P43405 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14913891 | 0.89 | ALDH1A1 (0.61) | ALDH1A1RAB9ANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL4712695 | 0.88 | ALDH1A1 (0.65) | ALDH1A1RAB9ANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL17013516 | 0.86 | ALDH1A1 (0.62) | ALDH1A1RAB9ANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL1522370 | 0.86 | PPARG (0.62) | SMN1; SMN2HTTHSD17B10KDM4EPPARG | |
| SCHEMBL28518879 | 0.85 | SMN1; SMN2 (0.58) | ALDH1A1RAB9ANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL16274792 | 0.84 | ALDH1A1 (0.60) | ALDH1A1RAB9ANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL1521580 | 0.84 | ALDH1A1 (0.76) | ALDH1A1RAB9AMAPTSMN1; SMN2POLB | |
| SCHEMBL34462345 | 0.84 | NPSR1 (0.65) | ALDH1A1RAB9ANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL1313596 | 0.84 | SYK (0.79) | ALDH1A1RAB9ANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL12904539 | 0.83 | STAT6 (0.58) | SYKPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20050075331-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2005-04-07 | — | — | US | disclosed |
| US-20040167123-A1 | Anti-infective agents | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040162285-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-08-19 | — | — | US | disclosed |
| US-20040097492-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-20 | — | — | US | disclosed |
| US-20040087577-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-06 | — | — | US | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097492-A1 | Anti-infective agents | POLR1C, RPL5, POLB | ALDH1A1 1434/4885RAB9A 2572/4885NPSR1 4323/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | ALDH1A1 389/4885RAB9A 2919/4885NPSR1 1840/4885 |
| US-20130137673-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | ALDH1A1 2512/4885RAB9A 2232/4885NPSR1 3747/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | ALDH1A1 261/4885RAB9A 3627/4885NPSR1 2720/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | ALDH1A1 327/4885RAB9A 3440/4885NPSR1 2570/4885 |
| US-20040162285-A1 | Anti-infective agents | POLR1C, RPL5, POLB | ALDH1A1 1434/4885RAB9A 2572/4885NPSR1 4323/4885 |
| US-20040167123-A1 | Anti-infective agents | SERPINB1, CYP51A1, ZC3HAV1 | ALDH1A1 891/4885RAB9A 2546/4885NPSR1 4037/4885 |
| US-20050075331-A1 | Anti-infective agents | RPL35, POLI, POLRMT | ALDH1A1 1592/4885RAB9A 2459/4885NPSR1 4146/4885 |
| US-20040087577-A1 | Anti-infective agents | POLR1C, RPL5, POLB | ALDH1A1 1434/4885RAB9A 2572/4885NPSR1 4323/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | ALDH1A1 327/4885RAB9A 3440/4885NPSR1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.